Dollars and Jens
Tuesday, January 27, 2004
 
More on Sanofi
Following yesterday's big news, today's Wall Street Journal has a profile of the CEO of Sanofi, Jean-Francois Dehecq:
Today [Plavix] is Sanofi's second-biggest earner, and could rake in €6 billion in sales in 2006, analysts estimate. According to Andrew Pendrill, an analyst in London for ABN Amro, Plavix, which is marketed in the U.S. by Bristol-Myers, represents €15 of the €50 share price for Sanofi in recent weeks.

Some analysts speculate that the potential early loss of the Plavix patent, which is being challenged in a U.S. court, may have prompted Sanofi's run at Aventis. Mr. Dehecq disagrees. "You don't launch operations of this type based on the timing of things you don't control," he says.
I think that's the dumbest statement I've heard in the last week from somebody not running for president.

- posted by Steven @ 11:50 AM

Powered by Blogger